Tweetovi

Blokirali ste korisnika/cu @SQZBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SQZBiotech

  1. 4. velj

    Today is . At SQZ, we are committed to our work developing targeted cell therapies to potentially address numerous types. Learn more about our first clinical trial focused on + solid tumors:

    Poništi
  2. 31. sij

    As many as 93% of could be prevented by screening & vaccination. Yet, in 2012, 8 million U.S. women ages 21 to 65 reported they had not been screened for cervical cancer in the last 5 years. Learn more about screening options here:

    Poništi
  3. 30. sij

    We are excited to announce that the first patient in the Ph1 evaluating our autologous comprised of SQZ-engineered APCs for HPV+ tumors has started treatment. Click here to read more about this pivotal company milestone:

    Poništi
  4. 28. sij

    This month we are recognizing SQZ member, Pushkal Garg, MD. Dr. Garg is the chief medical officer at & brings 2 decades of experience in drug development to the SQZ BoD. Learn more about the exceptional SQZ board here:

    Poništi
  5. 23. sij

    SQZ AACs have the potential to address multiple indications. Learn more about AACs and their unique mechanism of action here:

    Poništi
  6. 22. sij

    Today's article by previews what is to come in 2020 from SQZ! 2020 is a big year with progress in our SQZ APC clinical trial for the treatment of HPV+ solid tumors & more advances developing our AAC immunotherapy program for :

    Poništi
  7. 17. sij

    Some types of are linked to cervical cell changes that, if not detected early, can increase a woman’s risk for . Learn 10 facts about & from :

    Poništi
  8. 13. sij

    We are at in San Francisco this week! We look forward to connecting with the community and discussing our platform that has the potential to be broadly applicable across many diseases.

    Poništi
  9. 12. sij

    Tomorrow, SQZ CEO, Armon Sharei, will participate in the @LifeSci_PR panel led by ’s . Armon & other CEOs will discuss leveraging new technologies to tackle prevalent conditions. Interested in attending? RSVP:

    Poništi
  10. 7. sij

    We are developing for indications using two different approaches to stimulate antigen-specific immune activation for the treatment of . Learn more about our cell engineering platform:

    Poništi
  11. 3. sij

    January is . that 13,000 women in the U.S. are diagnosed with each year? We are currently recruiting patients with HPV+ cervical cancer for our Ph. 1 clinical trial. Learn more here:

    Poništi
  12. 31. pro 2019.

    that HPV+ tumors represent about 5% of cancers worldwide? Click here to learn more about SQZ’s first clinical trial focused on therapies to treat HPV+ solid tumors:

    Poništi
  13. 17. pro 2019.

    We recently announced our proprietary cell therapy approach to , SQZ AACs. The aim of the program is to leverage the mechanisms of endogenous APCs, using red blood cells to deliver antigen and prime T cell response against . Read more

    Poništi
  14. 11. pro 2019.

    This month we are recognizing SQZ member, Zafi Avnur. Zafi currently serves as CSO at Quark Venture & was a champion for the SQZ & partnership while she served as Global Head of Academic Innovation at Roche. Learn more:

    Poništi
  15. 5. pro 2019.

    that head & neck cancers account for approx. 4% of all cancers in the U.S. & are more than twice as common among men than women? SQZ’s first clinical program focuses on HPV+ tumors, including . Learn more about our Phase 1 trial here:

    Poništi
  16. 2. pro 2019.

    Tomorrow, SQZ will be presenting at the ISI HEALTHCONx Conference at 9:30 am ET. Click here for presentation details:

    Poništi
  17. 28. stu 2019.

    Happy from your friends at SQZ! Today and every day we are for the opportunity to develop cell therapies with the potential to impact patients suffering from a range of diseases. 🦃

    Poništi
  18. 26. stu 2019.

    that can cause several different types of ? Visit website to learn more about :

    Poništi
  19. 25. stu 2019.

    Marc Elia, a member of our BoD since 2018, has over 20 years’ experience in biotech, including as founder of M28 Capital Management. He is passionate about SQZ & eager to see our team assess the impact of large-scale antigen presentation in cancer.

    Poništi
  20. 22. stu 2019.

    SQZ CEO Armon Sharei was featured in discussing the exciting potential of the SQZ platform, our recent evolution into a company developing therapies for patients & key themes in the and space. Check it out!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·